LEXINGTON, Mass., Jan. 5, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that James Dentzer,
President and Chief Executive Officer of Curis, will present at the
H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The
presentation will be available for on-demand viewing
starting on Monday, January 11,
2021 at 6:00 am ET.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. A replay of the webcast will be
available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with
non-Hodgkin's lymphoma and in a Phase 1 trial in patients with
acute myeloid leukemia and myelodysplastic syndromes. In addition,
Curis is engaged in a collaboration with ImmuNext for development
of CI-8993, a monoclonal anti-VISTA antibody, which is
currently undergoing testing in a Phase 1a/1b trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis' website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright--co-bioconnect-2021-virtual-conference-301201028.html
SOURCE Curis, Inc.